Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
诺华拟斥资最高20亿美元收购Excellergy及其下一代Xolair候选药物

With its blockbuster drug Xolair set to face biosimilar competition, Novartis said it will pay up to $2 billion in upfront and certain milestone payments to take Excellergy and its IgE antibody, which just entered a Phase 1 trial.
随着重磅药物Xolair即将面临生物类似药竞争，诺华表示将支付最高20亿美元的预付款及特定里程碑款项，以收购Excellergy及其刚进入一期临床试验的IgE 抗体。